These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34179175)

  • 1. Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration.
    Walters RR; Boucher JF; De Toni F
    Front Vet Sci; 2021; 8():687448. PubMed ID: 34179175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of an Anti-nerve Growth Factor Antibody (Frunevetmab) for the Treatment of Degenerative Joint Disease-Associated Chronic Pain in Cats: A Multisite Pilot Field Study.
    Gruen ME; Myers JAE; Lascelles BDX
    Front Vet Sci; 2021; 8():610028. PubMed ID: 34124212
    [No Abstract]   [Full Text] [Related]  

  • 3. Frunevetmab, a felinized anti-nerve growth factor monoclonal antibody, for the treatment of pain from osteoarthritis in cats.
    Gruen ME; Myers JAE; Tena JS; Becskei C; Cleaver DM; Lascelles BDX
    J Vet Intern Med; 2021 Nov; 35(6):2752-2762. PubMed ID: 34724255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections.
    Storrer A; Mackie JT; Gunew MN; Aslan J
    J Feline Med Surg; 2023 Nov; 25(11):1098612X231198416. PubMed ID: 37975186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease-Associated Pain: A Pilot Proof of Concept Study.
    Gruen ME; Thomson AE; Griffith EH; Paradise H; Gearing DP; Lascelles BD
    J Vet Intern Med; 2016 Jul; 30(4):1138-48. PubMed ID: 27334504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats.
    Gearing DP; Huebner M; Virtue ER; Knight K; Hansen P; Lascelles BD; Gearing RP; Drew AC
    J Vet Intern Med; 2016 Jul; 30(4):1129-37. PubMed ID: 27306920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain.
    Shoji S; Suzuki A; Gaitonde P; Cai CH; Marshall S
    Br J Clin Pharmacol; 2022 Jul; 88(7):3321-3334. PubMed ID: 35112378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats.
    Srinivas NR; Shyu WC; Weiner RS; Warner G; Comereski C; Tay LK; Greene DS; Barbhaiya RH
    Pharm Res; 1997 Jul; 14(7):911-6. PubMed ID: 9244149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087).
    Walsh SR; Gay CL; Karuna ST; Hyrien O; Skalland T; Mayer KH; Sobieszczyk ME; Baden LR; Goepfert PA; Del Rio C; Pantaleo G; Andrew P; Karg C; He Z; Lu H; Paez CA; Baumblatt JAG; Polakowski LL; Chege W; Janto S; Han X; Huang Y; Dumond J; Ackerman ME; McDermott AB; Flach B; Piwowar-Manning E; Seaton K; Tomaras GD; Montefiori DC; Gama L; Mascola JR;
    medRxiv; 2024 Jan; ():. PubMed ID: 38260276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
    Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
    Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
    Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
    Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
    Mayer KH; Seaton KE; Huang Y; Grunenberg N; Isaacs A; Allen M; Ledgerwood JE; Frank I; Sobieszczyk ME; Baden LR; Rodriguez B; Van Tieu H; Tomaras GD; Deal A; Goodman D; Bailer RT; Ferrari G; Jensen R; Hural J; Graham BS; Mascola JR; Corey L; Montefiori DC; ;
    PLoS Med; 2017 Nov; 14(11):e1002435. PubMed ID: 29136037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats.
    Doodnaught GM; Monteiro BP; Benito J; Edge D; Beaudry F; Pelligand L; Steagall P
    PLoS One; 2017; 12(4):e0176443. PubMed ID: 28445495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial.
    Steagall PV; Ruel HLM; Yasuda T; Monteiro BP; Watanabe R; Evangelista MC; Beaudry F
    BMC Vet Res; 2020 May; 16(1):154. PubMed ID: 32448336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies.
    Joseph D; Thoma C; Haeufel T; Li X
    Clin Pharmacokinet; 2022 Dec; 61(12):1771-1787. PubMed ID: 36451029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
    Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety, and Immunogenicity of Intravenous and Subcutaneous Single-Dose QX002N Injection in Healthy Subjects: A Randomized, Open, Parallel, Single-Center, Phase I Study.
    Shen ZW; Wu KQ; Jin TH; Zhao J; Jiang Q; Guo T; Fang M; Chen GL
    Rheumatol Ther; 2024 Aug; 11(4):977-988. PubMed ID: 38853228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis.
    Tran JQ; Othman AA; Mikulskis A; Wolstencroft P; Elkins J
    Clin Pharmacol; 2016; 8():9-13. PubMed ID: 26929672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.